Vascular Biogenics reports positive interim data

Vascular Biogenics Ltd. (Nasdaq: VBLT) reported positive interim results from a Phase 2 study of VB-111 in patients with recurring glioblasotoma. The stock price soared $1.63 to close at $7.22.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.